DIA Postpones Conference on Drug Discovery and Clinical Development in India
Due to the tragic events that have taken place in Mumbai, DIA has postponed its 3rd Annual Conference on Drug Discovery and Clinical Development in India (December 7-10, 2008).
DRUG INFORMATION ASSOCIATION (DIA) POSTPONES 3RD ANNUAL CONFERENCE ON DRUG DISCOVERY AND CLINICAL DEVELOPMENT IN INDIA
WHO:
Drug Information Association (DIA)
WHAT:
3rd Annual Conference on Drug Discovery and Clinical Development in India
WHERE:
Renaissance Mumbai Hotel and Convention Centre
Mumbai, India
WHEN:
December 7-10, 2008
WHY:
Due to the tragic events that have taken place in Mumbai, DIA has postponed its 3rd Annual Conference on Drug Discovery and Clinical Development in India (December 7-10, 2008). The DIA Board of Directors, operational staff, and members and volunteers express their sympathies to the many people affected by the past week’s events. DIA is currently making plans to present this conference in February 2009 and will contact you with updated information about specific dates as soon as this information becomes available.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
